Хайлтын үр дүнгүүд - Attard, G
- 32-н 1 - 20 үр дүнгүүдийг харуулж байна
- Дараагийн хуудас руу очих
-
1
Prostate epithelial stem cells -н Rizzo, S., Attard, G., Hudson, D. L.
Хэвлэсэн 2005текст -
2
-
3
-
4
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail -н Ong, M, Carreira, S, Goodall, J, Mateo, J, Figueiredo, I, Rodrigues, D N, Perkins, G, Seed, G, Yap, T A, Attard, G, de Bono, J S
Хэвлэсэн 2014текст -
5
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours -н Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Хэвлэсэн 2007текст -
6
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer -н Pezaro, C, Mukherji, D, Tunariu, N, Cassidy, A M, Omlin, A, Bianchini, D, Seed, G, Reid, A H M, Olmos, D, de Bono, J S, Attard, G
Хэвлэсэн 2013текст -
7
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer -н Omlin, A, J Pezaro, C, Zaidi, S, Lorente, D, Mukherji, D, Bianchini, D, Ferraldeschi, R, Sandhu, S, Dearnaley, D, Parker, C, Van As, N, de Bono, J S, Attard, G
Хэвлэсэн 2013текст -
8
Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer' -н Omlin, A, Pezaro, C J, Zaidi, S, Lorente, D, Mukherji, D, Bianchini, D, Ferraldeschi, R, Sandhu, S, Dearnaley, D, Parker, C, Van As, N, de Bono, J S, Attard, G
Хэвлэсэн 2014текст -
9
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone -н Salvi, S, Casadio, V, Conteduca, V, Burgio, S L, Menna, C, Bianchi, E, Rossi, L, Carretta, E, Masini, C, Amadori, D, Calistri, D, Attard, G, De Giorgi, U
Хэвлэсэн 2015текст -
10
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer -н Abdel-Aty, H., O’Shea, L., Amos, C., Brown, L.C., Grist, E., Attard, G., Clarke, N., Cross, W., Parker, C., Parmar, M., Vas As, N., James, N.
Хэвлэсэн 2023текст -
11
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone -н Lorente, D, Omlin, A, Ferraldeschi, R, Pezaro, C, Perez, R, Mateo, J, Altavilla, A, Zafeirou, Z, Tunariu, N, Parker, C, Dearnaley, D, Gillessen, S, de Bono, J, Attard, G
Хэвлэсэн 2014текст -
12
Visceral disease in castration-resistant prostate cancer -н Pezaro, C., Omlin, A., Lorente, D., Rodrigues, D. Nava, Ferraldeschi, R., Bianchini, D., Mukherji, D., Riisnaes, R., Altavilla, A., Crespo, M., Tunariu, N., de Bono, J., Attard, G.
Хэвлэсэн 2013текст -
13
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement -н Foster, C S, Dodson, A R, Ambroisine, L, Fisher, G, Møller, H, Clark, J, Attard, G, De-Bono, J, Scardino, P, Reuter, V E, Cooper, C S, Berney, D M, Cuzick, J
Хэвлэсэн 2009текст -
14
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone -н Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C. J., Petrylak, D. P., Attard, G., Shen, L., Fizazi, K., de Bono, J.
Хэвлэсэн 2017текст -
15
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer -н Attard, G, Clark, J, Ambroisine, L, Fisher, G, Kovacs, G, Flohr, P, Berney, D, Foster, CS, Fletcher, A, Gerald, WL, Moller, H, Reuter, V, De Bono, JS, Scardino, P, Cuzick, J, Cooper, CS
Хэвлэсэн 2007текст -
16
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer -н Attard, G, Clark, J, Ambroisine, L, Mills, I G, Fisher, G, Flohr, P, Reid, A, Edwards, S, Kovacs, G, Berney, D, Foster, C, Massie, C E, Fletcher, A, De Bono, J S, Scardino, P, Cuzick, J, Cooper, C S
Хэвлэсэн 2008текст -
17
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents -н Crespo, M, van Dalum, G, Ferraldeschi, R, Zafeiriou, Z, Sideris, S, Lorente, D, Bianchini, D, Rodrigues, D N, Riisnaes, R, Miranda, S, Figueiredo, I, Flohr, P, Nowakowska, K, de Bono, J S, Terstappen, L W M M, Attard, G
Хэвлэсэн 2015текст -
18
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer -н Leibowitz-Amit, R., Templeton, A. J., Omlin, A., Pezaro, C., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., Sridhar, S. S., Tannock, I. F., de Bono, J. S., Joshua, A. M.
Хэвлэсэн 2014текст -
19
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate can... -н Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C
Хэвлэсэн 2013текст -
20
Transcriptional profiling of primary prostate tumor in metastatic hormone sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAART... -н Hamid, A. A., Huang, H-C., Wang, V., Chen, Y-H., Feng, F., Den, R., Attard, G., Van Allen, E. M., Tran, P. T., Spratt, D. E., Dittamore, R., Davicioni, E., Liu, G., DiPaola, R., Carducci, M. A., Sweeney, C. J.
Хэвлэсэн 2021текст